Is Replimune Stock a Good Investment?
Replimune Investment Advice | REPL |
- Examine Replimune's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Replimune's leadership team and their track record. Good management can help Replimune navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Replimune's business and its evolving consumer preferences.
- Compare Replimune's performance and market position to its competitors. Analyze how Replimune is positioned in terms of product offerings, innovation, and market share.
- Check if Replimune pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Replimune's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Replimune Group stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Replimune Group is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Replimune Stock
Researching Replimune's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 96.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.41. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Replimune Group recorded a loss per share of 3.07. The entity had not issued any dividends in recent years.
To determine if Replimune is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Replimune's research are outlined below:
| Replimune Group is way too risky over 90 days horizon | |
| Replimune Group appears to be risky and price may revert if volatility continues | |
| Replimune Group has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (247.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Replimune Group currently holds about 395.08 M in cash with (192.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Replimune Group has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Replimune Faces Securities Class Action Following Stocks Collapse Amid FDAs Rejection of Melanoma Drug - Hagens Berman |
Replimune Quarterly Cash And Short Term Investments |
|
Replimune uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Replimune Group. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Replimune's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 16th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 16th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Replimune's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Replimune's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-11-14 | 2018-09-30 | -0.2 | -0.26 | -0.06 | 30 | ||
2023-05-18 | 2023-03-31 | -0.67 | -0.74 | -0.07 | 10 | ||
2021-08-06 | 2021-06-30 | -0.46 | -0.53 | -0.07 | 15 | ||
2023-08-03 | 2023-06-30 | -0.84 | -0.75 | 0.09 | 10 | ||
2024-11-05 | 2024-09-30 | -0.77 | -0.6753 | 0.0947 | 12 | ||
2020-02-13 | 2019-12-31 | -0.36 | -0.46 | -0.1 | 27 | ||
2022-08-04 | 2022-06-30 | -0.64 | -0.78 | -0.14 | 21 | ||
2024-02-08 | 2023-12-31 | -0.93 | -0.77 | 0.16 | 17 |
Replimune Target Price Consensus
Replimune target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Replimune's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Replimune analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Replimune stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Replimune Group, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationReplimune Target Price Projection
Replimune's current and average target prices are 7.55 and 21.88, respectively. The current price of Replimune is the price at which Replimune Group is currently trading. On the other hand, Replimune's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Replimune Target Price
Replimune Analyst Ratings
Replimune's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Replimune stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Replimune's financials, market performance, and future outlook by experienced professionals. Replimune's historical ratings below, therefore, can serve as a valuable tool for investors.Know Replimune's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Replimune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Replimune Group backward and forwards among themselves. Replimune's institutional investor refers to the entity that pools money to purchase Replimune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Omega Fund Management Llc | 2025-03-31 | 2 M | Boxer Capital Management, Llc | 2025-03-31 | 1.8 M | Geode Capital Management, Llc | 2025-03-31 | 1.7 M | Braidwell Lp | 2025-03-31 | 1.5 M | Millennium Management Llc | 2025-03-31 | 1.2 M | Mpm Oncology Impact Management Lp | 2025-03-31 | 987 K | Parkman Healthcare Partners Llc | 2025-03-31 | 950.4 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 949.9 K | Wellington Management Company Llp | 2025-03-31 | 936.4 K | Baker Bros Advisors Lp | 2025-03-31 | 11 M | T. Rowe Price Associates, Inc. | 2025-03-31 | 10.9 M |
Replimune's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 587.44 M.Market Cap |
|
Replimune's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.53) | |
| Return On Capital Employed | (0.60) | (0.63) | |
| Return On Assets | (0.51) | (0.53) | |
| Return On Equity | (0.66) | (0.63) |
Determining Replimune's profitability involves analyzing its financial statements and using various financial metrics to determine if Replimune is a good buy. For example, gross profit margin measures Replimune's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Replimune's profitability and make more informed investment decisions.
Evaluate Replimune's management efficiency
Replimune Group has return on total asset (ROA) of (0.3126) % which means that it has lost $0.3126 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6258) %, meaning that it created substantial loss on money invested by shareholders. Replimune's management efficiency ratios could be used to measure how well Replimune manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.53. The value of Return On Capital Employed is expected to slide to -0.63. At this time, Replimune's Net Tangible Assets are quite stable compared to the past year. Other Current Assets is expected to rise to about 12.7 M this year, although the value of Total Assets will most likely fall to about 387 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.06 | 4.37 | |
| Tangible Book Value Per Share | 5.06 | 4.37 | |
| Enterprise Value Over EBITDA | (3.00) | (3.15) | |
| Price Book Value Ratio | 1.24 | 1.30 | |
| Enterprise Value Multiple | (3.00) | (3.15) | |
| Price Fair Value | 1.24 | 1.30 | |
| Enterprise Value | 464.4 M | 527.2 M |
Effective leadership at Replimune drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 0.615 |
Basic technical analysis of Replimune Stock
As of the 31st of July, Replimune holds the Risk Adjusted Performance of 0.0758, semi deviation of 13.43, and Coefficient Of Variation of 1155.6. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Replimune, as well as the relationship between them. Please check Replimune Group variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Replimune Group is priced some-what accurately, providing market reflects its current price of 7.55 per share. Given that Replimune has jensen alpha of 1.38, we recommend you to check out Replimune Group's recent market performance to make sure the company can sustain itself at a future point.Replimune's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Replimune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Replimune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Replimune insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Replimune's Outstanding Corporate Bonds
Replimune issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Replimune Group uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Replimune bonds can be classified according to their maturity, which is the date when Replimune Group has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| SCGAU 5125 24 SEP 80 Corp BondUS76025LAB09 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Replimune's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Replimune's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0758 | |||
| Market Risk Adjusted Performance | 3.01 | |||
| Mean Deviation | 6.77 | |||
| Semi Deviation | 13.43 | |||
| Downside Deviation | 16.29 | |||
| Coefficient Of Variation | 1155.6 | |||
| Standard Deviation | 16.93 | |||
| Variance | 286.56 | |||
| Information Ratio | 0.0771 | |||
| Jensen Alpha | 1.38 | |||
| Total Risk Alpha | (1.84) | |||
| Sortino Ratio | 0.0802 | |||
| Treynor Ratio | 3.0 | |||
| Maximum Drawdown | 89.28 | |||
| Value At Risk | (7.19) | |||
| Potential Upside | 12.07 | |||
| Downside Variance | 265.42 | |||
| Semi Variance | 180.25 | |||
| Expected Short fall | (7.28) | |||
| Skewness | 1.64 | |||
| Kurtosis | 25.32 |
| Risk Adjusted Performance | 0.0758 | |||
| Market Risk Adjusted Performance | 3.01 | |||
| Mean Deviation | 6.77 | |||
| Semi Deviation | 13.43 | |||
| Downside Deviation | 16.29 | |||
| Coefficient Of Variation | 1155.6 | |||
| Standard Deviation | 16.93 | |||
| Variance | 286.56 | |||
| Information Ratio | 0.0771 | |||
| Jensen Alpha | 1.38 | |||
| Total Risk Alpha | (1.84) | |||
| Sortino Ratio | 0.0802 | |||
| Treynor Ratio | 3.0 | |||
| Maximum Drawdown | 89.28 | |||
| Value At Risk | (7.19) | |||
| Potential Upside | 12.07 | |||
| Downside Variance | 265.42 | |||
| Semi Variance | 180.25 | |||
| Expected Short fall | (7.28) | |||
| Skewness | 1.64 | |||
| Kurtosis | 25.32 |
Consider Replimune's intraday indicators
Replimune intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Replimune stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Replimune Corporate Filings
| 25th of July 2025 Other Reports | ViewVerify | |
8K | 22nd of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 23rd of May 2025 Other Reports | ViewVerify | |
| 15th of May 2025 Other Reports | ViewVerify |
Replimune Stock media impact
There is far too much social signal, news, headlines, and media speculation about Replimune that are available to investors today. This information is accessible both publicly - through Replimune's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Replimune-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Replimune news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Replimune relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Replimune's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Replimune alpha.
Replimune Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Replimune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
BC-Most Active Stocks
recently @ finance.yahoo.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Replimune Group Historical Investor Sentiment
Investor biases related to Replimune's public news can be used to forecast risks associated with an investment in Replimune. The trend in average sentiment can be used to explain how an investor holding Replimune can time the market purely based on public headlines and social activities around Replimune Group. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Replimune's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Replimune and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Replimune news discussions. The higher the estimate score, the more favorable the investor's outlook on Replimune.
Replimune Maximum Pain Price Across September 19th 2025 Option Contracts
Replimune's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Replimune close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Replimune's options.
Replimune Corporate Management
| Colin Love | Chief Officer | Profile | |
| Christopher Sarchi | Chief Officer | Profile | |
| Carolyn Trott | Senior Assurance | Profile | |
| Pamela Esposito | Chief Business Officer | Profile | |
| Paul Bullock | Chief Head | Profile | |
| Kari Jeschke | Senior Affairs | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Replimune's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.